The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|December 27, 2023
2023 Dermatology Conference Recap: Part 2
Author(s)Emma Andrus, Associate Editor
Catch up on Dermatology Times conference coverage from July through December of this year.
Advertisement
July
World Congress of Dermatology
Molecular Differentiation of Dermatologic Therapeutics With Christopher Bunick, MD, PhD Kidney Disease-Associated Pruritus and Managing Prurigo Nodularis: Treatment Pearls From Raj Chovatiya, MD, PhD Tildrakizumab Data Reveals Significant Wellbeing Improvement in Patients With Plaque Psoriasis
Society of Pediatric Dermatology (SPD) Meeting
Angelo Landriscina, MD, Describes the Impact of TikTok on Society and Patients The Correlation Between Skin Health and Housing Disparities Ophthalmologic Considerations for Pediatric Dermatologists
September
Maui Derm NP+PA Fall
A Hairy Q&A With Jerry Shapiro, MD Colleen Cotton, MD, Explains Conditions Often Mistaken For Pediatric Acne Finding Itch Relief For Patients With Seborrheic Dermatits
October
European Academy of Dermatology and Venereology (EADV) Congress
MoonLake Immunotherapeutics Announces 24-Week Data of Sonelokimab for HS Amlitelimab Significantly Improves Average EASI Scores in Phase 2b AD Study Arcutis Presents Positive Roflumilast Foam Data From ARRECTOR Trial in Scalp and Body PsO at EADV
Inflammatory Disease Summit
Reviewing IDS 2023 and Psoriasis Clinical Cases With Tristan Hasbargen, PA-C Breaking Down JAKs and TYKs
Fall Clinical Dermatology Conference
Bunick Busts 10 Myths On Boxed Warnings Adding Cabtreo to the Acne Vulgaris Tool Box Overcoming Early Career Conundrums and Burnout With Muneeb Shah, DO
Society of Dermatology Physician Assistants (SDPA) Annual Fall Conference
Lisa Swanson, MD, PhD: Clinical Pearls in Pediatric Dermatology 4 Tips and Considerations for Selecting a Systemic Treatment for Your Patients With Psoriasis Renata Block, MMS, PA-C: When We Collaborate, The Patient Wins
Integrative Dermatology Symposium
November
American Society of Dermatologic Surgery Annual Meeting
Mohs Surgery Improves Rates of Nodal Metastasis and Disease Specific Death in cSCC ASDS: Review of Lasers and Light-Based Therapies for Acne
American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Exploring Dx Issues in SOC Atopic Dermatitis at ACAAI Choosing Biologics for AD: Update Presented at ACAAI Practice Management Pearls From ACAAI: Tips for Going Green
December
Revolutionizing Vitiligo (ReV) Virtual Conference
Upadacitinib for Vitiligo Improves Patient Health-Related QoL After 24 Weeks Study Finds Association Between Vitiligo and Osteoporosis
Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock Patient Perspective: I Am More Than My Atopic Dermatitis 5-Year Safety Data Leaves Investigators Optimistic in Upadacitinib for AD Management
Review our full conference coverage from the year
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5